Glucophage (Metformin Hydrochloride)

Glucophage is indicated for the treatment of type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

• Used as first‑line oral therapy for newly diagnosed patients.
• Added to other antidiabetic agents when glycemic control is insufficient.
• May be combined with insulin in patients requiring intensified therapy.
• Utilized in patients with overweight or obesity to aid weight management.
• Prescribed to improve insulin sensitivity in metabolic syndrome contexts (off‑label in some regions).

The safety profile of Glucophage includes a range of adverse effects that vary in frequency and severity. Most patients tolerate the medication, but monitoring is advised during therapy.

Common

• Gastrointestinal upset such as nausea, abdominal discomfort, and diarrhea.
• Metallic taste in the mouth.
• Decreased appetite leading to mild weight loss.
• Vitamin B12 deficiency with long‑term use (monitoring recommended).
• Flatulence and abdominal bloating.

Serious

• Lactic acidosis, a rare but potentially fatal metabolic complication.
• Severe hypoglycemia when combined with insulin or sulfonylureas.
• Hepatotoxicity manifested by elevated liver enzymes.
• Acute pancreatitis, though rare, reported in some cases.

Before initiating Glucophage, clinicians should evaluate several patient‑specific factors to minimize risks and ensure appropriate use.

• Assess renal function; contraindicated in severe renal impairment.
• Review hepatic status; caution in liver disease.
• Evaluate for conditions predisposing to hypoxia or heart failure.
• Monitor for signs of lactic acidosis, especially after surgery or acute illness.
• Check vitamin B12 levels periodically during long‑term therapy.
• Use with caution in elderly patients due to increased risk of dehydration.
• Avoid in pregnancy unless benefits outweigh risks (consult obstetric guidance).

Glucophage may interact with other medicines, affecting its efficacy or increasing the risk of adverse events.

Avoid

• Concomitant use with iodinated contrast agents due to heightened lactic acidosis risk.
• Co‑administration with potent CYP2C8 inhibitors (e.g., gemfibrozil) that raise metformin plasma levels.
• Combining with high‑dose alcohol or sedatives that may precipitate hypoglycemia.

Use with caution

• Concurrent insulin or sulfonylureas, which can increase hypoglycemia risk.
• Diuretics and ACE inhibitors, requiring renal function monitoring.
• Radiographic contrast procedures, necessitating temporary discontinuation of Glucophage.
• Antiretroviral agents (e.g., protease inhibitors) that may alter metformin clearance.